Clinical trials in advanced stage lung cancer: a survey of patients' opinion about their treatment by Bojan Zaric et al.
20 MRM
Original Article / Articolo Originale 
Clinical trials in advanced stage lung cancer:
a survey of patients’ opinion about their
treatment 
Trial clinici nel tumore del polmone in stadio
avanzato: un’analisi dell’opinione dei pazienti
riguardo al trattamento  
Bojan Zaric1, Branislav Perin1, Aleksandra Ilic1, Ivan Kopitovic1, Jovan Matijasevic1, 
Ljiljana Andrijevic2, Nevena Secen1, Jelena Stanic1, Milorad Bijelovic3, Zdravko Kosjerina1, 
Milan Antonic1
1 Institute for Pulmonary Diseases of Vojvodina, Clinic for Pulmonary Oncology, Faculty of Medicine, University 
of Novi Sad, Serbia
2 Institute for Oncology of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
3 Institute for Pulmonary Diseases of Vojvodina, Clinic for Thoracic Surgery, Faculty of Medicine, University of Novi
Sad, Serbia
ABSTRACT
Background: The major aim of this study was to investigate
what patients with advanced stage lung cancer, enrolled in a
clinical trial, thought about their treatment. We also wanted
to investigate if there exist any characteristics that could
influence patients’ opinion about the clinical trial.
Patients and methods: Over the period from June 2008 to June
2009, 59 eligible patients were enrolled in this study. The
major inclusion criteria were: participation in a clinical trial,
previously treated advanced stage lung cancer, and good per-
formance status (ECOG 0-2). All patients were asked to
answer a questionnaire designed to investigate their impres-
sions about participation in a clinical trial. The questionnaire
was deposited in a sealed box which was opened at the end of
the study. We investigated a possible influence of age, gender,
education, lung cancer stage, chemotherapy line and tumor
type on the patients' opinion about some aspects of the clin-
ical trial.
Results: The majority of the patients were aware they were
participating in the clinical trial and a significant number of
them were very satisfied with the treatment. Of the investi-
gated factors, only the level of education had a statistically
significant influence on some of the questions raised in the
questionnaire.
Conclusions: Patients participating in clinical trials are satis-
fied with their treatment, ready to proceed with it and would
recommend it to other patients. It depends mainly on health
professionals to maintain this level of confidence and justify
their trust. 
Keywords: Chemotherapy, clinical investigation, clinical trial,
lung cancer, non small cell lung cancer (NSCLC), small cell
lung cancer (SCLC).
RIASSUNTO 
Razionale: Lo scopo principale di questo studio era valutare
ciò che pensano i pazienti con un tumore polmonare in stadio
avanzato arruolati in un trial clinico riguardo al trattamento
cui sono sottoposti. Desideravamo inoltre valutare se esistes-
se qualche caratteristica dei pazienti in grado di influenzare la
loro opinione sui trial clinici.
Pazienti e metodi: Nel periodo tra giugno 2008 e giugno 2009
sono stati inclusi in questo studio 59 pazienti. I principali cri-
teri di inclusione erano la partecipazione ad un trial clinico,
essere già stati trattati per un tumore polmonare in stadio
avanzato ed avere una buona condizione generale (punteggio
0-2 alla scala Eastern Cooperative Oncology Group). A tutti i
pazienti è stato richiesto di compilare un questionario dise-
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gnato per valutare le loro impressioni sulla partecipazione al
trial clinico. Il questionario era depositato in un contenitore
sigillato che veniva poi aperto al termine dello studio.
Abbiamo ricercato una possibile influenza di età, sesso, scola-
rità, stadiazione del tumore polmonare, tipologia di chemio-
terapia e di tumore sull’opinione del paziente riguardo alcuni
aspetti del trial clinico.
Risultati: La maggioranza dei pazienti era consapevole di par-
tecipare ad un trial clinico ed una quota significativa di loro
era molto soddisfatta del trattamento. Tra i fattori oggetto di
questa ricerca solo il livello di scolarità dimostrava un’in-
fluenza statisticamente significativa su alcuni dei punti toc-
cati dal questionario.
Conclusioni: I pazienti che partecipano a trial clinici sono sod-
disfatti del loro trattamento, desiderosi di continuarlo e di-
sposti a raccomandarlo ad altri pazienti. Dipende soprattutto
dai professionisti della salute mantenere questo livello di fi-
ducia e giustificare questo credito.
Parole chiave: Chemioterapia, studio clinico, tumore polmo-
nare, tumore polmonare non a piccole cellule (NSCLC), tumo-
re polmonare a piccole cellule (SCLC), valutazione clinica.   
INTRODUCTION
Lung cancer still remains one of the deadliest can-
cer types in the world. Both the incidence and mor-
tality are still high, equally among male and female
patients, in practically all parts of the world. Lung
cancer is still a leading cause of cancer related mor-
tality, with an overall 5-year survival < 20% in
Europe and USA. The estimated number of new 
cases of lung cancer in USA for 2009 is 219,440.
The estimated number of deaths in USA for 2009 is
even more discouraging: 159,390 [1-4].
Many prevention and political measures, such as
prohibition of smoking in public places or the ban-
ning of cigarette commercials, might contribute to a
decrease in morbidity and mortality. However,
these measures need time to show their true poten-
tial. In the past decade, we have observed a drop in
morbidity (mostly in squamous cell lung cancer)
due to the public measures and increased public
awareness, but mortality still remains alarmingly
high [5-8]. 
The introduction of novel chemotherapeutic agents,
the development of targeted therapy, the combina-
tion of standard chemotherapy with molecular tar-
geted therapy, and combinations with various radio-
therapy regimens, might result in a better survival of
lung cancer patients. Indeed, some clinical trials
with novel targeted therapy agents, or their combi-
nations with chemotherapy, have shown a signifi-
cant improvement in the disease free survival, or
even the overall survival. On the other hand, we
should always be cautious about the results of clin-
ical studies and wait for more data, or meta-analy-
ses before implementing these results in the clinical
practice [4,9-12]. Nevertheless, in the light of the
current situation regarding lung cancer mortality, it
is true that the most appropriate treatment for a pa-
tient is his/her inclusion in a clinical trial.
Practically all cancer societies, dealing with the
problem of lung cancer, recommend treatment in a
clinical trial setting [12-16]. 
However, in the hunt for a better survival and better
results, with a substantial number of patients in
clinical trials, what do we actually know about our
patients’ thoughts and feelings? What do they them-
selves know about their own condition and the
treatment itself? The regulations and rules for the
clinical trials are strict and defined, and all physi-
cians investigating the treatment of lung cancer ad-
here to these rules and regulations [14-18]. But still,
what do patients think and know about it? Many pa-
tients receive therapeutic benefits from participating
in clinical trials, even moreso than they are aware,
and in some cases these benefits exceed those that
standard care could provide. However, the patients
participating in clinical trials contribute not only to
their own and future patients' treatment benefits,
but also to the benefits of medicine and to science
itself. The physicians are aware of this fact, but are
the patients aware of the same fact, too?
The major aim of the study we conducted was to in-
vestigate what patients knew and thought about
their disease, about the options for their current and
future treatment, as well as about the clinical trial
they participated in. We wanted to investigate how
satisfied they were with the treatment in the clinical
trial (this is why we included only previously treat-
ed patients), and what they thought and knew about
the novel chemotherapy they were treated with. We
designed a short questionnaire in order to obtain
the answers to some of these questions. The second-
ary aim of the study was to investigate the influence
of age, gender, education, lung cancer type and
stage, chemotherapy duration and chemotherapy
line on the patients’ opinion about the disease,
treatment, and clinical trial.
PATIENTS AND METHODS
This was a prospective trial conducted at the Clinic
for Pulmonary Oncology of the Institute for
Pulmonary Diseases of Vojvodina, Serbia. The study
was carried out over a 1-year period, from July 2008
to July 2009, and it was approved by the institution-
al review and ethical board. All the patients who
agreed to participate in the study and answer the
questionnaire were informed about the study and
signed the informed consent form.
Of 86 patients who at the time participated in clin-
ical trials on administration of novel chemothera-
peutic agents, 59 met all the inclusion criteria and
were eligible for the study. The inclusion criteria
were: current participation in a phase II or III clini-
cal trial on non-small cell lung cancer (NSCLC) or
small cell lung cancer (SCLC), the treatment includ-
ing targeted molecular therapy, chemotherapy or
their combination, advanced stage (IIIB, IV) NSCLC
or extensive SCLC, second or third line chemother-
apy, good performance status graded by Eastern
Cooperative Oncology Group (ECOG) 0-2, and
willingness to participate in the study. The exclusion
criteria were: the first line chemotherapy, stage I –
IIIA NSCLC, limited SCLC, current or concurrent 





























7 ticipate in the study.
A specially designed questionnaire (Figure 1) was
given to each patient enrolled. The patients were
asked to answer the questionnaire after the third
course of the second or third line chemotherapy
regimen. All of the patients had sufficient time to
answer the questions and to place the question-
naires in the “answer box”. The “answer box” was a
sealed carton container placed in the main hall of
the clinic, enabling the patients to keep their priva-
cy and anonymity after completing the question-
naire. This approach provided privacy to the pa-
tients, and ensured true and honest answers. It was
explained to the patients that they should write their
QUESTIONNAIRE
The main purpose of this investigation is explained to you in the informed consent form you read and signed. If you wish, you can answer
the questions in this questionnaire. Answer the questions by simply circling the answer you think is appropriate. When you finish, please
put the questionnaire in the answer box located in the main lobby of the clinic.
Thank you for your participation.
1. Are you familiar with the nature of the disease you suffer from?
a) Yes b) No c) I am not sure
2. Do you know the type of lung cancer you suffer from?
a) Yes b) No c) I am not sure
3. Do you know what kind of chemotherapy for lung cancer you have so far received?
a) Yes b) No c) I am not sure
4. Are you aware in what stage your condition (lung cancer) currently is?
a) Yes b) No c) I am not sure
5. Have you received your previous chemotherapy in a regional hospital or at the Institute for Pulmonary Diseases 
of Vojvodina (IPBV)?
a) Regional hospital      b) IPBV      c) I am not sure
6. Do you understand that you are participating in the clinical trial with novel chemotherapy or targeted therapy drug?
a) Yes b) No c) I am not sure
7. Do you understand what a clinical trial is?
a) Yes b) No c) I am not sure
8. Have you read the entire Informed Consent Form (ICF) your physician gave you before you entered the clinical trial?
a)Yes b) No c) I am not sure
9. How satisfied are you with the information about the clinical trial you obtained from your physician or from the ICF?
a) Very satisfied      b) Satisfied      c) Not satisfied      d) I am not sure
10. Do you think that during the clinical trial period you will need additional information about the study treatment?
a) Yes b) No c) I am not sure
11. Do you think that by participating in a clinical trial you have a better chance for surviving the lung cancer?
a) Yes b) No c) I am not sure
12. Do you think that chemotherapy given within the clinical trial is better than the chemotherapy patients usually get?
a) Yes b) No c) I am not sure
13. Are you aware of the fact that you might not be treated with the investigational product in the clinical trial you are currently 
participating?
a) Yes b) No c) I am not sure
14. Do you think the investigational product (chemotherapy) given in the clinical trial you are currently participating in has fewer side 
effects than the chemotherapy you were previously treated with?
a) Yes b) No c) I am not sure
15. Do you think that the medical personnel (physicians and nurses) conducting this clinical trial have sufficient knowledge and training?
a) Yes b) No c) I am not sure
16. Do you think the physicians and nurses are more easily accessible to you because you are participaring in the clinical trial?
a) Yes b) No c) I am not sure
17. Do you think that your treatment within the clinical trial is better than the treatment of patients who are not participating 
in clinical trials?
a) Yes b) No c) I am not sure
18. How would you assess your treatment in the clinical trial so far?
a) Excellent      b) Very good      c) Good      d) Neither good nor bad      e) Bad
19. If there were an opportunity to join another clinical trial, after you finish the current one, would you join?
a) Yes b) No c) I am not sure
20. Would you recommend to other patients to join the clinical trial you have been participating in?
a) Yes b) No c) I am not sure
FIGURE 1: AD-HOC QUESTIONNAIRE TO INVESTIGATE PATIENTS’ IMPRESSIONS ABOUT PARTICIPATION IN A CLINICAL TRIAL
MRM 23
B Z
aric, B Perin, A
 Ilic, I Kopitovic, J M
atijasevic, L A
ndrijevic, N





Lung cancer trials and patient opinion – L’op
inione dei p





initials and date of birth in order to enable obtain-
ing other relevant data from their medical charts
needed for evaluation of the results to be performed
later. 
Descriptive statistics were generated for all study
variables, including the mean and standard devia-
tion for continuous variables and relative frequen-
cies for categorical variables. 
The variables concerning ’the patients’ satisfaction’
were treated as the data in nominal category. In or-
der to compare these answers according to gender,
cancer type, cancer stage, education level of pa-
tients and line of chemotherapy, we used Pearson’s
χ2 test with p < 0.05 as a significant level of proba-
bility. All statistical analyses were performed using
the SPSS for Windows, version 11.5 (SPSS Inc.,
Chicago, IL) software. 
RESULTS
Fifty-nine patients were included in this study. The
average age of the patients was 56 ± 10 years (range
36-73). The average chemotherapy duration was 11
± 4 months (range 3-19). There were 48 (81.4%)
male patients and 11 (18.6%) females included in
this study. Most patients (n = 32, 54.2%) had squa-
mous cell lung cancer diagnosed; small cell lung
cancer was diagnosed in 16 (27.1%) patients, and
adenocarcinoma in 11 (18.6%) patients. The major-
ity of the patients (30/59, 50.8%) had an advanced
stage IV NSCLC. Thirteen patients (22%) had stage
IIIB NSCLC. Extensive SCLC was investigated in 16
patients (27.2%). There were 17 patients (28.8%)
enrolled in phase II clinical trials versus 42 (71.2%)
in phase III clinical trials. The majority of the pa-
tients (32 or 54.2%) were high school graduates; 16
(27.1%) patients had a university degree, while 11
patients (18.6%) had elementary school education. 
An overview of the questions, and frequency and
percentage of the answers is presented in Table I.
The questions marked with an asterisk are ex-
plained further in the text. It is clear from the table
that all the patients who participated in both clini-
cal trials and our study were familiar with the nature
of their disease. A significant number of patients
knew the type of lung cancer they suffered from.
There was also a significant number of patients who
knew what kind of chemotherapy they received pri-
or to the enrollment in the clinical trial. The major-
ity of the patients were aware of their current lung
cancer stage. Question 5 addressed the place or in-
stitution where the patients received previous
chemotherapy. Most patients were previously treat-
ed in our institution (44/59 or 74.6%); 14 (23.7%)
patients were treated in the regional hospital, while
one patient did not know where he was treated.
Almost all patients (58/59 or 98.3%) knew that they
were participating in a clinical trial; the remaining
patient responded that he did not know he was par-
ticipating in a clinical study. The large majority of
patients (47/59 or 79.7%) said they understood
what “a clinical trial” was, but 12 patients (20.3%)
were not sure what “a clinical trial” means. One of
the most interesting results shows that 5 patients
(8.5%) did not read the entire informed consent
form (ICF). However, a significant number of pa-
tients (54/59 or 91.5%) had read the entire ICF.
Question 9 addressed the level of satisfaction with
the information about the treatment within the clin-
ical trial. Forty-three patients (72.9%) were very sat-
isfied with the information given by the investiga-
tors or provided in the ICF and 16 patients were sat-
isfied. There were no patients who were not satis-
fied or who were unable to answer question 9.
Practically equal numbers of patients thought they
would/would not require additional information
during the clinical trial period, i.e. 47.5% and
49.2% of the patients, respectively. 
One of the most important findings obtained in the
study was the opinion of patients that the
chemotherapy given in the clinical trial would give
them a better chance for survival. A significant
number of patients (93.2%) thought they had a bet-
ter chance of survival in the clinical trial, and 6.8%
of the patients were not sure about it. There was al-
so a large number of patients who answered that
chemotherapy given in the clinical trial was better
than the therapy used previously. Forty-eight pa-
tients (81.4%) thought that chemotherapy in the
clinical trial was better than the “usual” chemother-
apy, 2 patients thought it was not better, while 9 pa-
tients (15.3%) were not sure. A majority of patients
(98.3%) understood that during the clinical trial
they might not receive the investigational product.
There were 38 patients (64.4%) who thought that
chemotherapy given in the clinical trial had fewer
side effects, 16 who thought the contrary (that
chemotherapy given in the clinical trial did not have
fewer side effects), and 5 (8.5%) who were not sure.
There were 57/59 (96.6%) patients who thought
that the medical personnel conducting the clinical
trial had sufficient knowledge and skills. This shows
that a majority of patients believe that their doctors
and nurses are adequately trained. All the patients
enrolled in the study expressed the opinion that the
physicians and nurses were more easily accessible
to them because they participated in the study. A
significant number of patients (57/59 or 96.6%) be-
lieved the treatment within a clinical trial was better
than the treatment given to patients not included in
trials. Two remaining patients were not sure about
this issue. A majority of the patients (89.8%) graded
their overall treatment in the clinical trial as excel-
lent. Five patients (8.5%) assessed their treatment as
very good, while one patient assessed it as good.
There were no patients who assessed their treatment
as “neither good nor bad” or “bad”. Interestingly,
88.1% of the patients answered that they would
participate in future clinical trials when they fin-
ished the treatment in the current one. This means
that a significant number of patients would like to
continue the treatment within the clinical trial. On
the other hand, two patients (3.4%) would not any
more participate in clinical trials, while 5 patients
(8.5%) were not sure about it. The majority of pa-





























7 TABLE I: PATIENTS’ RESPONSES PER RESPONSE CATEGORY (NUMBER AND %) TO EACH ITEM OF THE 
QUESTIONNAIRE    
Question Answers
Yes No I am not sure
n/% n/% n/%
1. Are you familiar with the nature 59/100 0/0 0/0
of disease you suffer from?
2. Do you know the type of lung cancer 50/84.7 0/0 9/15.3
you suffer from?
3. Do you know what kind of chemotherapy 58/98.3 0/0 1/1.7
for lung cancer you received so far?
4. Are you aware at what stage 44/74.6 1/1.7 14/23.7
your condition (lung cancer) currently is?
5. Have you received your previous chemotherapy 
in a regional hospital or at the Institute for Pulmonary 
Diseases of Vojvodina (IPBV)?*
6. Do you understand that you are participating 58/98.3 0/0 1/1.7
in a clinical trial with novel chemotherapy 
or a targeted therapy drug?
7. Do you understand what a clinical trial is? 47/79.7 0/0 12/20.3
8. Have you read the entire Informed 54/91.5 5/8.5 0/0
Consent Form (ICF) your physician gave 
before you entered the clinical trial?
9. How satisfied are you with the information about 
the clinical trial you obtained from your physician 
or from the ICF?*
10. Do you think that during the clinical trial 28/47.5 29/49.2 2/3.4
period you will need additional information 
about the study treatment?
11. Do you think that by participating in a clinical 55/93.2 0/0 4/6.8
trial you have a better chance for surviving 
the lung cancer?
12. Do you think that chemotherapy given within 48/81.4 2/3.4 9/15.3
the clinical trial is better than the chemotherapy 
patients usually get?
13. Are you aware of the fact that you might 58/98.3 0/0 1/1.7
not be treated with the investigational product 
in the clinical trial you are currently participating?
14. Do you think that the investigational product 38/64.4 16/27.1 5/8.5
(chemotherapy) given in the clinical trial you are 
currently participating in has fewer side effects than 
the chemotherapy you were previously treated with?
15. Do you think that medical personnel 57/96.6 1/1.7 1/1.7
(physicians and nurses) conducting this clinical trial 
have sufficient knowledge and training?
16. Do you think that physicians and nurses are more 59/100 0/0 0/0
easily accessible to you because you are participating 
in the clinical trial?
17. Do you think that your treatment within the clinical 57/96.6 0/0 2/3.4
trial is better than the treatment of patients who 
are not participating in clinical trials?
18. How would you assess your treatment 
in the clinical trial so far?*
19. If there would be an opportunity to join another 52/88.1 2/3.4 5/8.5
clinical trial, after you finish the current one, 
would you join?
20. Would you recommend to other patients 56/94.9 1/1.7 2/3.4
to join the clinical trial you have been participating in?
Answers on questions marked with asterisk are explained in the text.
Questions are consecutively stated in Figure 1.
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ical trial treatment to other patients. One of the pa-
tients would not recommend it, while two were not
sure about it.
Several factors that could potentially influence the
patients' answers were evaluated in the multivariate
analysis, including age, gender, lung cancer type,
current lung cancer stage, chemotherapy line, pa-
tients' education level, and duration of chemother-
apy treatment. However, only one factor proved in-
fluential on the patient’s answers on specific ques-
tions: and that factor was the patients' education
level. A statistically significant higher number of pa-
tients (p = 0.008) with university education knew
the exact type of lung cancer they suffered from
compared to patients with high or elementary
school level of education. There was also a statisti-
cally significant number of patients with a univer -
sity degree (p < 0.001) who knew the exact stage of
their disease, a significant number of them 
(p = 0.004) understood what the “clinical trial” was.
There was also a significant number of patients with
university degree who had read the entire informed
consent form (p = 0.02) and a significant number of
them thought that they would require additional in-
formation regarding the trial (p = 0.001). On the
other hand, there was a statistically significant num-
ber of patients with high school education level
who believed that the investigational product given
in the chemotherapy trial caused less side effects 
(p = 0.04). There was also a statistically significant
number of patients with a lower education level
than university degree (high school) who would join
another clinical trial after completion of the current
one (p = 0.01).
DISCUSSION
The findings of this study reveal that the majority of
the patients included in the study had an advanced
stage NSCLC, primarily the squamous cell lung can-
cer. This is due to the fact that squamous cell lung
cancer is the most prevalent type of lung cancer in
our country, but selection bias also played a signif-
icant role: most of the studies from which our pa-
tients were drawn were examining chemotherapy in
squamous cell lung cancer. That is the main reason
why the distribution of lung cancer types does not
correlate with the general distribution of lung can-
cer types in most published studies. Lung cancer is
usually diagnosed in its late or advanced stage; in
our country almost 80% of patients with NSCLC are
diagnosed with an advanced stage lung cancer. The
majority of patients with SCLC are also diagnosed
in an extensive disease stage. In most countries
there are no clear screening programs for lung can-
cer. The same is true for Serbia, but here we are also
facing low public health awareness. The political
measures for prevention of lung cancer are still in
their infancy in Serbia, as in many developing
countries, and it is too early to expect the results un-
til in the next few years. 
Our patients were asked to answer the question-
naire after the third cycle of the clinical trial
chemotherapy regimen in order to be able to com-
pare their previous experience with the current one.
The patients included in this study were receiving
second or third line chemotherapy within the clini-
cal trial in which they were participating, so they al-
ready had substantial experience with chemo -
therapy. The results show that most patients know
the true nature of their disease and even the type of
lung cancer they suffer from, suggesting that pa-
tients are well informed about their condition and
disease. A frank approach to a patient, giving
him/her a thorough explanation of the disease char-
acteristics and the treatment, is a cornerstone for
gaining the patient's trust. It can also create a rela-
tionship in which it is easier to explain to the patient
the significance of participation in the clinical trial,
if the patient qualifies for it. This is particularly im-
portant in low income countries where clinical trial
therapy, even for control groups, is a big step for-
ward with respect to the therapy patients would
usually get. We often have the situation that the
physicians are highly interested in the clinical trial,
not from the financial standpoint, but because it is
the only way for patients to be treated as recom-
mended by the guidelines. This is probably one of
the reasons why we are often among the sites with
the highest enrollment in many clinical trials. 
The adequate approach to the patient with lung
cancer can also be observed through a significant
number of the patients who knew what type of
chemotherapy they received prior to the enrollment
in the clinical trial. However, this may be related to
the fact that the majority of the patients received
that therapy in our institution where the institutional
policy is to explain to patients what kind of therapy
they will receive. One of the most important results
showed that the majority of the patients knew that
they were participating in the clinical trial, except
for one patient. One of the reasons might be insuf-
ficient engagement of the physician or inability to
completely understand the informed consent form
(ICF). The ICF is usually too robust for a patient to
read it completely, and without significant help
from the physician the patient can hardly under-
stand all that is written in the document. Whatever
the reason for that one negative answer is, it stands
as a warning. We must pay due attention to all pa-
tients in clinical trials all the time they are under our
treatment. The fact that 8.5% of the patients did not
read the entire ICF represents also an alarming find-
ing. As stated before, ICFs usually provide more de-
tailed information about the trial than an investiga-
tor can give during the interview with a patient. The
multivariate analysis showed that a significant num-
ber of the patients with a university degree read the
entire ICF. This suggests we should pay more atten-
tion to less educated patients, especially when pro-
viding information and ICF documentation. On the
other hand, the scientific management and study
protocol teams should pay more attention to the
concept of the ICF, taking into consideration its
length and the patients' ability to understand what





























7 number of pages, with complicated explanations
and medical terms are usually not understandable
for the patient. No matter how a patient may be mo-
tivated to read the entire document, 20 pages of text
are a bit too much. One factor is also very impor-
tant - the translation from English to native lan-
guages. These translations are usually made by pro-
fessional translators and not medical professionals,
leading to a literary translation which is sometimes
hard to understand even for physicians. 
The overall satisfaction with the level of information
provided was significantly high in our group, sug-
gesting that our study teams provided sufficient and
relevant information. We tried to avoid potential bi-
ases by providing a level of anonymity to the pa-
tients who dispatched their answers in a sealed car-
ton box placed in the clinic lobby. We also ex-
plained to the patients that the sincerity of their an-
swers was of major importance, and that whatever
answers they gave, it would not have any influence
on their further treatment. The level of education in-
fluenced the requirement of the patients for addi-
tional information although the number of patients
who answered that they would require additional
information and those who answered that they
wouldn't was practically equal. This is related to the
fact that more educated patients expect a more de-
tailed update on their condition. The patients' belief
and trust in the treatment is also reflected by a sig-
nificant number of patients who answered that they
believed that chemotherapy given in the clinical tri-
al is better than the “usual” chemotherapy. The an-
swer might be biased by an excessive explanation
of the advantages for participation in the clinical tri-
al given by the physician. However there were two
patients with university degree who gave a negative
answer, and 9 patients who were not sure, and they
represent almost 20% of the patients included in
the study. These results suggest that the possible bias
could be minimal, and that the patients really be-
lieved the trial chemotherapy was better. The impor-
tant issue is that chemotherapy given in the clinical
trial protocol in developing countries is more ad-
vanced, from the medical point of view, and pa-
tients are able to recognize this fact. 
It is very important that a significant majority of the
patients know that they might not receive the inves-
tigational product during the trial. That shows that
the patients are aware of the study design, its bene-
fits and pitfalls and they still want to participate,
even though they have the opportunity to withdraw
from the trial whenever they want. Still, they are sat-
isfied with the treatment and consider their physi-
cians as trustworthy, well educated and knowledge-
able. The patients enrolled in the clinical trial think
that because of their participation in the trial, nurses
and physicians are more easily accessible to them.
This might be true - it is a fact that more time and
special care is provided to the patients in the clini-
cal trial. It is sometimes required by the protocol of
the trial itself (to perform more examinations or
more detailed examinations, more lab tests, to
check the patients' condition several times a day).
All this creates an impression of special care re-
ceived, so the patients usually feel more comfort-
able and more appreciated. This might be also one
of the reasons why the majority of the patients ex-
pressed the opinion that their treatment was better
than the treatment of the patients not included in
the trial. A significant number of our patients quali-
fied their overall treatment in the clinical trial as ex-
cellent. This is a direct consequence of the number
and quality of provided services. Certainly, the
quality and engagement of the sponsors who pro-
vided travel reimbursement and refreshments could
play a significant role in such assessment of the
treatment. On the other hand, the fact is that the
combination of drugs in the clinical trials in ad-
vanced stage lung cancer nowadays includes target-
ed therapy alone or in combination with
chemotherapy. This results in fewer side effects and
better clinical improvement compared to standard
chemotherapy available in developing countries.
The patients can observe and feel the improvement
and they usually feel satisfied with the treatment.
The physicians are eager to monitor the patients
more carefully, ready to dedicate more time and at-
tention to them in order to detect a result of the
treatment and record the patients' current condi-
tion. The physician’s interest is generated on one
side by scientific and, on the other, by financial rea-
sons. But, no matter what generates it, a higher
physicians’ vigilance results in better care for the
patients and this is what matters most. This of course
is the case in developing countries; the situation in
more developed economies could be substantially
different. 
The overall success of the treatment in the clinical
trials in our study is testified by the fact that a statis-
tically significant number of patients would join an-
other trial after they finish the current one, and a
significant majority of the patients would recom-
mend the treatment in clinical trials to other pa-
tients. That should be one of the goals of clinical tri-
als in advanced lung cancer. The majority of the
published guidelines suggest that the best treatment
for patients with advanced stage lung cancer is in a
clinical trial. But if one patient recommends the tri-
al to another, the trial itself gains popularity and im-
portance among the patients. There is no better mo-
tivation for a patient to join a trial than the recom-
mendation of a friend or a fellow patient. We en-
countered situations in which a significant number
of patients were interested in joining the study be-
cause they had heard about it form other patients.
However, this implies a huge responsibility for the
physicians: a very selective choice of the trials with
special concern for a full ethical discolsure of the
study, taking of course into consideration the med-
ical justification. 
A major disadvantage of this study is that the ques-
tionnaire was developed by our own study team
that included medical physicians and non-medical
staff (pulmonologists and medical oncologists, nurs-
es, statisticians and IT engineers). The questionnaire
did not undergo all the testing phases in concor-
MRM 27
B Z
aric, B Perin, A
 Ilic, I Kopitovic, J M
atijasevic, L A
ndrijevic, N





Lung cancer trials and patient opinion – L’op
inione dei p





dance with the guidelines for questionnaires in clin-
ical trials. However, our intent was to make a sur-
vey of the patients’ opinion, not to measure their
satisfaction, because that would require a fully de-
veloped and tested questionnaire, which is not
available in that form. With the form of the ques-
tionnaire we created, we tried to minimize the bias-
es and maximize the quality of the answers used for
the analysis. 
CONCLUSION
Clinical trials in advanced stage lung cancer are
currently the best option for the treatment of pa-
tients with that condition. Our study showed that
the patients included in several clinical trials have a
very positive attitude toward the current trial and
clinical trials in general. The overall satisfaction
with the treatment was very high, suggesting that
the patients think they received the best possible
care, and probably they think so because they are
enrolled in a clinical trial. The patients' confidence
and trust in their physicians and nurses is very firm
and the majority of patients completely trusted their
physicians. The major conclusion of this study
could be that not only do the physicians have high
hopes from the trials, but that patients understand
what the trial is and have high hopes too. This study
showed that the patients would recommend the tri-
al to other patients, proving that they are aware of
the fact that they could, with their opinion and ex-
perience, help others, too. 
The only factor identified in this study that possibly
influences the patients’ opinion about the treatment
is the level of education. We should adjust our ap-
proach to each individual patient with a special
concern about the level of education. Our recom-
mendation to study teams and protocol writers
would be to pay special attention to the ICF, its
length and amount of information provided by it. In
conclusion, our patients do believe in clinical trials
and they do believe in us. It is difficult to say how
much effort we must additionally invest to obtain
better results and longer survival of patients with
lung cancer. One thing is sure: we must give our
best to justify the confidence and the hope our pa-
tients place in us.
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